children
neurogen
bladder
frequent
posit
urin
cultur
howev
determin
posit
urin
cultur
repres
urinari
tract
infect
uti
oppos
urinari
tract
colon
utc
inde
half
urin
cultur
children
neurogen
bladder
posit
absenc
posit
urin
cultur
diagnost
uti
children
furthermor
wide
accept
definit
uti
children
neurogen
contribut
signific
variabl
way
clinician
diagnos
treat
suspect
uti
defint
uti
children
clinician
reli
assess
symptom
diagnos
uti
howev
combin
symptom
gener
consid
diagnost
uti
fever
abdomin
pain
vomit
absenc
anoth
sourc
symptom
increas
incontin
discomfort
catheter
less
clear
inde
seri
adult
neurogen
bladder
symptom
found
nonspecif
absenc
accur
biomark
good
predict
accuraci
uti
children
neurogen
bladder
specif
urinalysi
ua
paramet
good
sensit
specif
diagnosi
uti
gener
pediatr
ua
result
less
use
diagnos
uti
patient
neurogen
like
relat
fact
compon
ua
either
marker
inflamm
ie
pyuria
leukocyt
esteras
indic
presenc
organ
eg
nitrit
specif
uti
popul
accur
object
method
diagnos
uti
popul
need
inde
rapidli
rise
trend
antibioticresist
organ
cultur
urin
children
neurogen
although
multifactori
one
reason
behind
trend
larg
number
antibiot
children
receiv
identif
biomark
sensit
specif
uti
urolog
complex
patient
popul
would
improv
abil
appropri
prescrib
antibiot
object
pilot
studi
identifi
novel
marker
uti
children
neurogen
bladder
ideal
marker
uti
children
neurogen
bladder
specif
infect
rather
gener
inflamm
howev
target
approach
identifi
novel
marker
uti
limit
small
number
candid
protein
therefor
perform
pilot
studi
consist
unbias
analysi
urin
children
neurogen
bladder
either
uti
utc
identifi
novel
candid
marker
uti
pilot
studi
secondari
analysi
patient
residu
urin
sampl
enrol
work
design
determin
predict
accuraci
singl
protein
diagnos
patient
neurogen
bladder
activ
perform
clean
intermitt
catheter
cic
follow
center
urin
cultur
sent
part
clinic
care
august
novemb
elig
particip
origin
studi
includ
patient
present
urodynam
routin
urin
cultur
sent
institut
present
evalu
potenti
uti
patient
met
inclus
criteria
ie
presenc
neurogen
bladder
activ
perform
cic
initi
identifi
electron
health
record
verona
wi
use
intern
classif
diseas
revis
code
neurogen
bladder
spina
bifida
follow
initi
identif
research
team
perform
manual
review
patient
medic
record
confirm
inclus
criteria
met
elig
patient
flag
vigilanz
corpor
minneapoli
mn
realtim
lab
monitor
softwar
sent
automat
notif
via
email
research
team
flag
patient
urin
sampl
sent
clinic
laboratori
residu
urin
obtain
use
work
patient
exclud
follow
reason
met
kdigo
criteria
acut
kidney
sign
symptom
time
present
dialysisdepend
studi
approv
institut
review
board
patient
includ
studi
drawn
origin
cohort
identifi
describ
patient
uti
chosen
includ
mass
spectrometri
phase
studi
suffici
residu
urin
analysi
met
criteria
uti
describ
confirm
unequivoc
uti
manual
chart
review
five
patient
uti
randomli
chosen
met
criteria
patient
utc
elig
includ
suffici
urin
analysi
patient
utc
met
criteria
closest
age
patient
uti
select
chart
patient
utc
review
ensur
symptom
concern
uti
urin
sampl
obtain
use
work
within
hour
initi
collect
time
kept
refriger
sampl
centrifug
rmin
minut
temperatur
addit
use
point
sampl
process
supernat
aliquot
microcentrifug
tube
volum
urin
avail
per
patient
vari
number
aliquot
save
vari
aliquot
per
patient
sampl
label
uniqu
stickon
barcod
frozen
immedi
sampl
process
store
follow
protocol
sampl
undergon
freezethaw
cycl
time
analysi
patient
includ
uti
group
met
follow
criteria
growth
greater
equal
coloni
form
unit
per
millilit
cfuml
known
uropathogen
urin
cultur
urinari
white
blood
cellshighpow
field
spun
urin
specimen
follow
sign
symptom
fever
greater
abdomin
pain
new
back
pain
new
worsen
incontin
pain
catheter
malodor
cloudi
urin
adapt
definit
uti
origin
publish
maddenfuent
modif
chang
colonycount
uti
cfuml
accord
american
academi
pediatr
guidelin
diagnosi
patient
posit
urin
cultur
meet
criteria
includ
utc
group
growth
group
includ
patient
neg
urin
cultur
exclud
patient
whose
urin
cultur
grew
either
fungi
mixtur
unidentifi
organ
five
patient
unequivoc
uti
patient
utc
posit
urin
cultur
clinic
symptom
includ
initi
identif
candid
marker
sampl
volum
reduc
filter
laemmli
buffer
protein
concentr
measur
use
pierc
nm
protein
assay
kit
thermo
scientif
assay
compat
higher
concentr
deterg
maintain
greater
linear
rang
standard
coomassi
dyebind
assay
eg
bradford
assay
sampl
run
cm
bistri
gel
use
mop
morpholino
propanesulfon
acid
run
buffer
region
lane
well
dye
front
excis
trypsin
digest
result
peptid
extract
control
lane
pool
togeth
recoveri
digest
peptid
sampl
determin
via
nanodrop
analysi
result
peptid
sampl
tag
indic
itraq
reagent
use
vendor
instruct
sampl
itraq
set
mix
base
peptid
nanodrop
read
load
onto
sciex
nanoflow
lcmass
spectrometri
system
previous
set
contain
one
common
control
sampl
made
equal
protein
mixtur
sampl
cohort
measur
protein
ratio
singl
common
control
allow
cross
comparison
rel
protein
level
among
sampl
cohort
proteinpilot
softwar
sciex
use
identifi
protein
determin
rel
quantit
run
merg
search
run
identifi
full
scope
protein
detect
across
group
proteinpilot
data
process
protein
align
templat
softwar
sciex
protein
signific
foldchang
uti
utc
group
chang
averag
abund
across
group
identifi
protein
interest
oper
blind
sampl
group
analysi
stage
unblind
necessari
interpret
result
remain
sampl
initi
cohort
exclud
use
protein
identif
stage
use
measur
protein
interest
includ
nonsecretori
ribonucleas
mybiosourc
llc
san
diego
ca
prosaposin
apolipoprotein
lifespan
bioscienc
seattl
wa
commerci
avail
assay
kit
use
measur
candid
protein
remain
sampl
urin
creatinin
measur
nephelometri
use
standard
valu
limit
detect
lod
protein
imput
standard
valu
categor
variabl
compar
chisquar
fisher
exact
test
appropri
normal
distribut
continu
variabl
compar
either
student
test
analysi
varianc
anova
post
hoc
tukey
appropri
nonnorm
distribut
variabl
biomark
valu
compar
kruskalw
test
receiv
oper
characterist
roc
curv
gener
biomark
interest
use
select
cutoff
threshold
outcom
uti
associ
sensit
specif
statist
analysi
done
use
r
version
packag
data
work
avail
request
author
five
patient
uti
patient
utc
includ
mass
spectrometri
analysi
patient
growth
utc
uti
includ
assay
analysi
differ
age
sex
race
etiolog
neurogen
bladder
presenc
mitrofanoff
bladder
augment
utc
uti
mass
spectrometri
analysi
assay
analysi
higher
proport
male
growth
group
compar
utc
group
differ
group
tabl
protein
identifi
use
mass
spectrometri
protein
set
protein
consist
detect
quantifi
least
patient
group
subject
test
analysi
establish
signific
chang
supplement
figur
exampl
protein
detect
one
group
less
group
howev
case
level
protein
detect
group
well
outsid
signific
p
valu
remov
contamin
hemoglobin
sever
immunoglobulin
protein
like
link
minor
blood
contamin
andor
inflammatori
respons
protein
identifi
p
protein
interest
base
least
increas
decreas
test
group
includ
haptoglobin
apolipoprotein
alphaamylas
interatrypsin
inhibitor
heavi
chain
antigen
liver
fatti
protein
prosaposin
figur
protein
interest
identifi
mass
spectrometri
measur
assay
addit
set
sampl
apolipoprotein
alphaamylas
prosaposin
alphaamylas
abl
analyz
sampl
valu
lod
signific
differ
either
normal
nonnorm
concentr
either
apolipoprotein
figur
normal
prosaposin
concentr
significantli
higher
uti
compar
growth
p
utc
p
normal
significantli
higher
uti
compar
utc
p
although
differ
normal
concentr
uti
growth
figur
nonnorm
prosaposin
significantli
higher
uti
compar
growth
p
utc
p
differ
nonnorm
group
area
curv
auc
apolipoprotein
show
poor
candid
marker
uti
apolipoprotein
howev
prosaposin
display
auc
suggest
moder
util
distinguish
utc
uti
prosaposin
identifi
cutoff
prosaposin
poor
sensit
good
specif
outcom
uti
tabl
use
mass
spectrometri
identifi
novel
urinari
protein
candid
marker
uti
children
neurogen
bladder
differenti
express
protein
measur
urin
sampl
potenti
serv
marker
aid
differenti
uti
utc
three
protein
identifi
protein
interest
includ
valid
phase
due
limit
amount
urin
avail
liver
fatti
protein
identifi
protein
interest
includ
known
marker
tubular
therefor
potenti
confound
result
similarli
chose
investig
interatrypsin
inhibitor
heavi
chain
also
elev
patient
decreas
renal
urin
haptoglobin
report
elev
multipl
condit
includ
lupu
diabet
urotheli
given
presenc
haptoglobin
multipl
condit
like
would
specif
marker
uti
therefor
chosen
protein
interest
type
transmembran
glycoprotein
whose
main
ligand
hyaluron
constitut
express
almost
initi
believ
play
role
lymphocyt
sinc
found
multipl
function
includ
lymphocyt
activ
celltocel
adhes
hyaluron
metabol
embryon
develop
cellular
adhes
migrat
lymphocyt
monocyt
prolifer
capac
serv
role
innat
immun
system
defens
stimul
antimicrobi
peptid
addit
may
also
play
role
pathogenesi
certain
infect
includ
uti
inde
escherichia
coli
bind
hyaluron
mechan
interact
invad
urotheli
furthermor
knockout
mice
demonstr
increas
bacteri
clearanc
follow
transurethr
inocul
compar
wild
type
differ
note
neutrophil
accumul
howev
increas
seen
urinari
work
like
relat
fact
constitut
express
urotheli
one
respons
bladder
infect
exfoli
superfici
urotheli
like
increas
concentr
urinari
seen
patient
uti
work
result
exfoli
urotheli
cell
prosaposin
parent
protein
saposin
glycoprotein
togeth
saposin
multipl
function
bodi
includ
glycosphingolipid
transport
facilit
sphingolipid
activ
glycosphingolipid
well
develop
homeostasi
male
reproduct
prosaposin
also
exist
secretori
protein
describ
milk
cerebrospin
fluid
semin
major
function
prosaposin
associ
saposin
occur
within
context
neurolog
system
saposin
also
play
role
within
immun
system
inde
saposin
play
critic
role
activ
invari
natur
killer
cell
assist
access
cell
microbi
furthermor
natur
killer
tcell
activ
implic
host
respons
e
coli
taken
togeth
data
shown
suggest
prosaposin
may
facilit
innat
immun
respons
uti
thu
partial
explain
role
potenti
marker
uti
two
protein
apolipoprotein
studi
within
confirm
arm
work
show
differ
utc
uti
apolipoprotein
mani
function
wide
studi
within
context
lipid
metabol
neurolog
howev
may
also
play
role
modul
inflamm
set
apolipoprotein
may
bind
ligand
implic
innat
immun
system
howev
known
ligand
apolipoprotein
consist
mainli
lipid
within
highdens
lipoprotein
plasma
accordingli
known
function
apolipoprotein
involv
neurolog
scant
literatur
util
protein
set
infect
possibl
apolipoprotein
present
urin
patient
neurogen
bladder
due
role
within
neurolog
system
underli
etiolog
neurogen
bladder
also
known
eosinophilderiv
neurotoxin
protein
found
granul
within
eosinophil
initi
describ
urin
later
found
structur
eosinophilderiv
protein
upregul
allerg
inflamm
parasit
furthermor
antivir
activ
specif
singlestrand
rna
induc
migrat
dendrit
cell
neutrophil
monocyt
urinari
describ
parasit
describ
context
bacteri
infect
presenc
protein
urin
patient
may
relat
dendrit
cell
migrat
statist
signific
protein
sever
patient
uti
group
elev
level
although
differ
median
concentr
work
need
understand
role
one
exist
uti
prosaposin
low
sensit
good
specif
uti
suggest
greatest
util
marker
identifi
children
may
infect
rather
may
serv
identifi
children
like
infect
need
specif
marker
uti
popul
current
use
marker
uti
ie
pyuria
leukocyt
esteras
nitrit
greater
sensit
specif
marker
greater
util
popul
identifi
children
safe
monitor
antibiot
therapi
rate
antibioticresist
organ
increas
significantli
faster
rate
children
neurogen
bladder
compar
without
neurogen
great
need
identifi
children
requir
antibiot
prosaposin
may
serv
specif
marker
uti
children
neurogen
bladder
futur
work
need
larger
cohort
determin
appropri
cutoff
associ
predict
accuraci
report
conflict
result
identif
valid
arm
work
report
signific
elev
prosaposin
uti
compar
utc
result
mass
spectrometri
suggest
protein
increas
utc
compar
uti
one
possibl
explan
differ
method
normal
sampl
load
mass
spectromet
base
total
protein
concentr
literatur
mix
presenc
proteinuria
cystiti
data
suggest
presenc
tubular
proteinuria
like
patient
identif
arm
pyelonephr
chosen
base
unequivoc
present
uti
therefor
patient
like
higher
degre
proteinuria
lead
smaller
amount
urin
use
analysi
convers
urin
load
confirmatori
assay
base
volum
concentr
therefor
possibl
tubular
proteinuria
patient
uti
led
conflict
result
inde
enzymelink
immunosorb
assay
elisa
result
display
increas
prosaposin
utc
compar
children
growth
urin
cultur
increas
magnifi
uti
group
ad
specif
suggest
util
specif
marker
uti
children
neurogen
bladder
one
main
limit
work
lack
standard
definit
uti
patient
neurogen
bladder
signific
variat
clinic
manag
bacteriuria
patient
popul
well
definit
uti
use
therefor
chosen
definit
appear
literatur
use
research
realiz
still
imperfect
definit
mitig
potenti
misclassif
bia
perform
addit
review
patient
chart
ensur
ambigu
around
classif
either
infect
colon
howev
combin
definit
use
plu
clinic
acumen
still
imperfect
thu
lack
valid
way
differenti
uti
colon
remain
limit
work
limit
includ
limit
number
patient
use
arm
work
inabl
better
match
patient
uti
utc
mass
spectrometri
arm
furthermor
perform
stabil
studi
protein
interest
unabl
determin
whether
prolong
storag
could
affect
level
howev
urin
sampl
use
work
store
amount
time
anticip
like
affect
result
differenti
upregul
protein
final
limit
use
urin
creatinin
normal
use
urin
creatinin
standard
protein
urin
concentr
may
ideal
method
standard
cohort
given
differ
bodi
habitu
anthropomorph
measur
popul
product
serum
creatinin
directli
impact
util
urin
creatinin
method
normal
therefor
use
urin
creatinin
may
confound
result
pilot
work
show
urinari
prosaposin
urinari
concentr
increas
children
neurogen
bladder
uti
compar
utc
prosaposin
elev
children
uti
compar
neg
cultur
urinari
prosaposin
may
help
identifi
children
neurogen
bladder
point
care
requir
antibiot
treatment
uti
although
work
need
valid
result
